Altering Heparin Cofactor II at VAL439 (P6) either Impairs Inhibition of Thrombin or Confers Elastase Resistance^[*]

Summary

Heparin cofactor II (HCII) is plasma glycoprotein and thrombin inhibitor of the serpin type previously shown to inhibit thrombin in the absence of its N-terminal 74 amino acids, and to be cleaved by neutrophil elastase (NE) at two sites: I66-F67 and V439-G440, the P6-P5 bond of the reactive center loop. We examined the contribution of Val439 to the reaction of HCII with thrombin and NE. Hexahistidine-tagged HCII proteins lacking residues 1-66 (H6Δ66HCII) containing either the wild-type Val 439 or one of six substitutions were expressed in E. coli. The rates of heparin-catalyzed thrombin inhibition of the V439L, C, or R variants were reduced at least 80-fold compared to wild-type H6Δ66HCII, while those of the F, S, or W variants were largely unchanged. Following controlled exposure to NE in the presence of heparin, these latter variants retained 3.5to 4.5-fold more residual anti-thrombin activity than wild-type H6Δ66HCII treated in the same manner. This resistance arose due to deflection of NE attack from V439-G440 to secondary sites. The F, S, or W V439 variants exhibited a similar or greater degree of NE resistance when re-expressed as full-length hexahistidine-tagged HCII proteins, suggesting that the I66-F67 NE site is not well recognized in non-glycosylated HCII. Of these full-length variants, the V439F was the most active, exhibiting only a 2-fold reduction in its heparin-catalyzed rate of thrombin inhibition. HCII can therefore be made NE-resistant without severely compromising its capacity to inhibit thrombin.

Keywords

Heparin cofactor II - thrombin - elastase

^* This study was supported by Grant-In-Aid T4154 from the Heart and Stroke Foundation of Ontario.

• References

• 1 Hunt LT, Dayhoff MO. A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. Biochem Biophys Res Commun 1980; 95: 864-71.
• 2 Carrell RW, Pemberton PA, Boswell DR. The serpins: evolution and adaptation in a family of protease inhibitors. Cold Spring Harb Symp Quant Biol 1987; 52: 527-35.
• 3 Irving JA, Pike RN, Lesk AM, Whisstock JC. Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res 2000; 10: 1845-64.
• 4 Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman JO, Shore JD. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 1995; 270: 25309-12.
• 5 Olson ST, Bock PE, Kvassman J, Shore JD, Lawrence DA, Ginsburg D, Bjork I. Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-enzyme complexes. J Biol Chem 1995; 270: 30007-17.
• 6 Stratikos E, Gettins PG. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 angstroms and full insertion of the reactive center loop into beta-sheet A. Proc Natl Acad Sci 1999; 96: 4808-13.
• 7 Fa M, Bergstrom F, Hagglof P, Wilczynska M, Johansson LB, Ny T. The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites. Structure Fold Des 2000; 08: 397-405.
• 8 Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-6.
• 9 Carrell RW, Owen MC. Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 1985; 317: 730-2.
• 10 Pratt CW, Tobin RB, Church FC. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. J Biol Chem 1990; 265: 6092-7.
• 11 Takaki A, Enfield DL, Thompson AR. Cleavage and inactivation of Factor IX by granulocyte elastase. J Clin Invest 1983; 72: 1706-15.
• 12 Wu K, Urano T, Ihara H, Takada Y, Fujie M, Shikimori M, Hashimoto K, Takada A. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: evaluation of its physiologic relevance in fibrinolysis. Blood 1995; 86: 1056-61.
• 13 ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000; 28: S9-11.
• 14 Thijs LG. Coagulation inhibitor replacement in sepsis is a potentially useful clinical approach. Crit Care Med 2000; 28: S68-73.
• 15 Eldering E, Huijbregts CC, Nuijens JH, Verhoeven AJ, Hack CE. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils. J Clin Invest 1993; 91: 1035-43.
• 16 Cunningham MA, Blajchman MA, Sheffield WP. Impact of mutations at the P4 and P5 positions on the reaction of antithrombin with thrombin and elastase. Thromb Res 1997; 88: 171-81.
• 17 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-9.
• 18 Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967; 27: 157-62.
• 19 Bode W, Meyer Jr E, Powers JC. Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based. Biochemistry 1989; 28: 1951-63.
• 20 Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease?. Nat Struct Biol 1995; 02: 96-113.
• 21 Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM. Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli . Biochemistry 1988; 27: 752-9.
• 22 Green S, Issemann I, Sheer E. A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res 1988; 16: 369.
• 23 Liaw PC, Austin RC, Fredenburgh JC, Stafford AR, Weitz JI. Comparison of heparin-and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. J Biol Chem 1999; 274: 27597-604.
• 24 Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222: 525-59.
• 25 Van Deerlin VM, Tollefsen DM. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. J Biol Chem 1991; 266: 20223-31.
• 26 Bauman SJ, Church FC. Enhancement of heparin cofactor II anticoagulant activity. J Biol Chem 1999; 274: 34556-65.
• 27 Han JH, Van Deerlin VM, Tollefsen DM. Heparin facilitates dissociation of complexes between thrombin and a reactive site mutant (L444R) of heparin cofactor II. J Biol Chem 1997; 272: 8243-9.
• 28 Gils A, Declerck PJ. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1. J Biol Chem 1997; 272: 12662-6.
• 29 Chaillan-Huntington CE, Gettins PW, Huntington JA, Patston PA. The P6-P2 region of serpins is critical for proteinase inhibition and complex stability. Biochemistry 1997; 36: 9562-70.
• 30 Plotnick MI, Schechter NM, Wang ZM, Liu X, Rubin R. Role of the P6-P3 region of the serpin reactive loop in the formation and breakdown of the inhibitory complex. Biochemistry 1997; 36: 14601-8.
• 31 Ciaccia AV, Willemze AJ, Church FC. Heparin promotes proteolytic inactivation by thrombin of a reactive site mutant (L444R) of recombinant heparin cofactor II. J Biol Chem 1997; 272: 888-93.
• 32 Sheehan JP, Tollefsen DM, Sadler JE. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans. J Biol Chem 1994; 269: 32747-51.
• 33 Baglin TP, Carrell RW, Church FC, Esmon CT, Huntington JA. Crystal structures of native and S195A thrombin-complexed heparin cofactor II reveal its allosteric mechanism of action. Thromb Haemost 2001; 86S: OC61.
• 34 Zendehrouh P, Lu A, Zuo Y, Picard V, Bock SC. Development and properties of neutrophil-resistant human antithrombins. Thromb Haemost 1999; 82S: 28-9.
• 35 Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-23.